Thus, if validated this would advocate that CX3CL1 concentrations are a biomarker that when elevated would suggest the clinician could initiate ILD directed therapy, which could prevent a further decline in lung function from progressive SSc-ILD. This evidence concerns the gene CX3CL1 and interstitial lung disease.